Nouscom Revenue

Biotechnology Research • Basel, Basel, Switzerland • 51-100 Employees

Nouscom revenue & valuation

Annual revenue	$7,499,999
Revenue per employee	$112,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$24,000,000
Total funding	$81,000,000

Key Contacts at Nouscom

Jai Raj Kashyap

Director Clinical Data Management

Craig Taylor

Sr Director, Business Operations & Development

Juan De Alvaro

Medical Director

Nabakumar Sau

Managing Director

Company overview

Headquarters	Bäumleingasse 18, BS, Basel-City 4051, CH
Phone number	+390696036299
Website	nouscom.com
NAICS	541714
SIC	873
Employees	51-100
Socials

Nouscom Email Formats

Nouscom uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@nouscom.com), used 95.6% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@nouscom.com	95.6%
{first initial}.{last name}	j.doe@nouscom.com	4.4%

About Nouscom

Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Nouscom has 31 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore Nouscom's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-12-14	6	$73,400,000
2024-04-21	6	$7,600,000

Funding Insights

$81,000,000

Total funding amount

$7,600,000

Most recent funding amount

Number of funding rounds

Nouscom Tech Stack

Discover the technologies and tools that power Nouscom's digital infrastructure, from frameworks to analytics platforms.

SiteGround

Hosting

iubenda

Cookie compliance

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

jQuery

JavaScript libraries

PHP

Programming languages

Microsoft Advertising

Advertising

WordPress

Blogs

Google Analytics

Analytics

Bootstrap

UI frameworks

Yoast SEO

SEO

Google Tag Manager

Tag managers

Frequently asked questions

Nouscom is located in Basel, Basel, CH.

You can reach Nouscom at +390696036299.

Nouscom generates an estimated annual revenue of $7,499,999. This revenue figure reflects the company's market position and business performance in its industry.

Nouscom has an estimated valuation of $24,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Nouscom has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Nouscom has raised a total of $81,000,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.